Cramer discussed 4 charts, and he thinks these 4 stocks, which form the acronym FANGs, are the new tech stocks to watch. Facebook (FB) has a ceiling of resistance at $32, and if it pulls back to $23, Cramer would buy, since FB is showing a bullish cup and handle formation. Amazon (AMZN) has roared out 10% from its head and shoulders formation. If the stock goes below its support of $250, it might be worth buying, particularly if it drops to $215. Netflix (NFLX) is in a bullish pennant pattern, but it has had a huge move, and the stock may move sideways for a while. Google (GOOG) has risen significantly, but may have 10% more upside

Last year, Eaton (ETN) acquired Cooper Industries for $13 billion, and now Eaton, a diversified industrial, has more exposure to the electric business. Eaton reported that revenues have risen 7.4% and management said end markets are strong. Eaton's stock rose 4.93% on the news, and is up 14% since Cramer last spoke to the CEO in June. CEO Sandy Cutler said, "Eaton and Cooperhave had strong positions withdifferent products and services.With our ability to bring themtogether in gas and inmining, in commercialconstruction and data centers, webecome a much more capablesupplier." Cutler said he looks forward to a pickup of business in China. Cramer congratulated Cutler on a great quarter for Eaton.

Allergan (AGN) is an example of a healthcare company that has succeeded in finding multiple uses for its leading product. Not only is Botox a leading anti-wrinkle treatment, but it has been used successfully to treat migraines, and its most recent application is for treating overactive bladder. As a result, Botox sales are expected to double by 2020. AGN's forecast surpassed analyst expectations; it should be noted that AGN is usually conservative with guidance. AGN has risen 20% since Cramer last spoke to the CEO in September and is up 160% since Cramer got behind it four years ago. CEO David Pyott discussed a new treatment for migraines through inhalation. Allergan is developing a treatment for macular degeneration which, if approved, would entail fewer injections than the current drug. Cramer recommends buying Allergan on any pullback.

We only use your contact details to reply to your request for more information.We do not sell the personal contact data you submit to anyone else.

Thank you for your interest in Seeking Alpha PROWe look forward to contacting you shortly for a conversation.

Thank you for your interest in Seeking Alpha PRO

Our PRO subscription service was created for fund managers, and the cost of the product is
prohibitive for most individual investors.
If you are an investment professional with over $1M AUM and received this message
in error, click here and you will be contacted shortly.

Thank you for your interest in Seeking Alpha PROWe look forward to contacting you when we have an individual investor product ready!